Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on April 13, 2017, reporting an event that occurred on April 10, 2017. The filing addresses a corporate governance decision regarding non-employee Board compensation.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, or cash flow data. However, it discloses the following specific financial figures:
- Strategic Investment: The Company received a $20,000,000 strategic investment from Tianjin Pharmaceutical Group International Holdings Co., Ltd.
- Deferred Compensation: Previously deferred annual compensation for non-employee Board members was $100,000 per director.
Material Changes
The primary material change is the reinstatement of non-employee Board compensation for the period between July 1, 2016, and July 1, 2017. This decision was driven by an improvement in the Company's cash position resulting from the aforementioned $20 million investment.
Management Commentary and Unusual Items
Management and the Compensation Committee determined that the improved liquidity allowed for the payment of previously deferred compensation. Directors may elect to receive this compensation in cash, conditional stock option grants (subject to NASDAQ rules), or a combination of both. No other risks, contingencies, or guidance are disclosed in this specific filing.
Investor Verification Checklist
- Verify the exact amount of the $20,000,000 investment received from Tianjin Pharmaceutical Group International Holdings Co., Ltd. and its impact on the balance sheet.
- Confirm the total number of non-employee directors to calculate the aggregate cash or equity impact of the reinstated $100,000 per director compensation.
- Review the Company's cash position prior to and after the investment to understand the liquidity constraints that led to the initial deferral.
- Check subsequent filings for the specific election made by directors regarding cash versus stock option compensation.